Filing Flows › Sabra Health Care REIT (SBRA) › Stock forecast & fair value
Sabra Health Care REIT (SBRA) stock forecast and fair value
Sabra Health Care REIT (SBRA) trades at $19.29. 14 analysts' median price target is $22.00 (+14%), from $19.00 to $25.00. Across 20 valuation methods the middle fair value is $15.35 (-20%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| P/E vs peers | $5.31 | $7.31 | $9.87 | -62% |
| P/E vs peers, weighted | $6.93 | $9.79 | $19.74 | -49% |
| P/E vs peers, matched | $5.78 | $8.91 | $14.69 | -54% |
| P/E vs peers, growth-adjusted | $5.34 | $8.98 | $15.12 | -53% |
| EV/Sales vs peers | $5.01 | $21.97 | $31.27 | +14% |
| EV/Sales vs peers, weighted | $21.56 | $32.33 | $40.33 | +68% |
| EV/Sales vs peers, matched | $4.28 | $14.23 | $38.93 | -26% |
| Residual income | $8.53 | $8.86 | $9.22 | -54% |
| P/FFO vs REIT peers | $12.37 | $14.62 | $21.10 | -24% |
| P/FFO vs REIT peers, weighted | $14.56 | $18.64 | $26.87 | -3% |
Sabra Health Care REIT's latest quarter
Sabra Health Care REIT, Q3 2026: revenue $250M (+31% year over year), operating margin 11.5%, net earnings $28.6M, operating cash flow $129M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for SBRA stock?
The median of 14 analysts' 12-month targets is $22.00, +14% from $19.29; the range is $19.00 to $25.00. The average rating is buy.
What is Sabra Health Care REIT's fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $1.62 and $32.33, with a middle value of $15.35 against a price of $19.29. Each method's assumptions are on the page.
Does Sabra Health Care REIT usually beat earnings estimates?
It beat the consensus EPS estimate in 40% of the quarters on record.
Is SBRA stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.